Revolutionizing the Treatment of Autoimmune Diseases
Addressing significant unmet needs in the field of autoimmunity through the development of novel patented therapies for treatment of disease.
AnTolRx’s vision is to build a platform that selectively targets pathogenic immune cells providing a unique tolerogenic signal to induce an anti-inflammatory phenotype and better treat diseases.
We will be presenting data on AnTolRx's antigen-specific nanoformulation platform. Join us in Woods Hole, MA, on October 12-13th, 2019. http://www.newenglandimmunology.org
ANTOLRX ANNOUNCES PFIZER EXERCISES OPTION TO LICENSE IMMUNE TOLERANCE THERAPY FOR POTENTIAL TREATMENT OF TYPE 1 DIABETES
CAMBRIDGE, Mass., March 5,2019 – AnTolRx, Inc., a private biotechnology company and a leader in immune tolerance, today announced that Pfizer Inc. (NYSE: PFE) has exercised the option granted under a June 2016 agreement to license an immune...